Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles
NCT ID: NCT04193930
Last Updated: 2022-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2021-01-01
2021-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Bologna criteria: At least two of the following three features must be present:
(i) Advanced maternal age (≥40 years). (ii) Previous Poor responders (≤3 oocytes with a conventional stimulation protocol).
(iii) An abnormal ovarian reserve test Most controlled ovarian hyperstimulation regimens currently used for expected poor responders are based on using a high daily dose (300- 450 IU/day) of exogenous gonadotropins. Giving a high gonadotropin dose obviously increases the cost of in vitro fertilization, a consequence that would be acceptable if paralleled by an improvement in in vitro fertilization outcome. Unfortunately, however, the available data suggest that increasing the daily gonadotropins dose may increase the number of retrieved oocytes, but not the final success rate of in vitro fertilization.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin in Intracytoplasmic Sperm Injection Cycles
NCT03088631
Letrozole in Assisted Reproductive Technology
NCT02429999
Delayed Embryo Transfer in Poor Responders
NCT02431689
Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response
NCT02798653
Timing of Initiation of Luteal Phase Support in Poor Responders Undergoing IVF/ICSI
NCT03938064
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Soft ovarian stimulation protocol
Letrozole
Oral tablet letrozole 2,5 mg/twice daily for 5 days
Menotropins
150 IU of highly purified menotropins intramuscular
conventional ovarian stimulation protocol
Menotropins
150 IU of highly purified menotropins intramuscular
recombinant Follicular stimulating hormone
recombinant Follicular stimulating hormone 300- 400 IU
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letrozole
Oral tablet letrozole 2,5 mg/twice daily for 5 days
Menotropins
150 IU of highly purified menotropins intramuscular
recombinant Follicular stimulating hormone
recombinant Follicular stimulating hormone 300- 400 IU
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previous Poor responders (≤3 oocytes with a conventional stimulation protocol).
* An abnormal ovarian reserve tests
Exclusion Criteria
* Endocrine or metabolic diseases like hyperprolactinoma, hypothyroidism,...etc
* Patients with a severe male factor abnormality. 4-Patients with systemic disease such as chronic renal disease, chronic liver disease, etc
40 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Khairy Ali
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women Health Hospital - Assiut university
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICSI_PR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.